Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection

NCT05105828 | Completed

• 1 other identifier: Share wave fibro scan in HCC
• Study Type: observational
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Shear wave electrography score allows stratification of HCC risk in a noninvasive and reliable way and can guide the surveillance strategy for HCC in patients with CLD

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• Shear wave elastography score

  it measures liver stiffness as it is a rapid technique taking less than 5 min that can be easily performed at bedside or in outpatient clinic,according to the manufacturer's recommendations and the machine scale result ranges from 2.5 to 75 kPa with normal value around 5.5 kPa

  through study completion, an average of 1 year

Study Arms (2)

post Hepatitis C patients with hepatocellular carcinoma

post Hepatitis C patients with hepatocellular carcinoma above 18 years

Diagnostic Test: Share wave fibro scan

control group

post Hepatitis C patients without hepatocellular carcinoma above 18 years

Diagnostic Test: Share wave fibro scan

Interventions

Share wave fibro scan DIAGNOSTIC_TEST

Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis

control group; post Hepatitis C patients with hepatocellular carcinoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Post hepatitis C with HCC above 18 years

You may qualify if:

• Post hepatitis C with HCC

You may not qualify if:

• hepatic encephalopathy, ascites or pregnancy, hepatorenal syndrome or hepato-pulmonary syndrome, right side heart failure (liver congestion), extra hepatic tumors, history of liver transplantation, cholestasis, and hepatitis B patient

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

Location

Related Publications (4)

• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 May 17;383(9930):1749-61. doi: 10.1016/S0140-6736(14)60121-5. Epub 2014 Jan 28.

  PMID: 24480518 BACKGROUND

• Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014 Jan 14;20(2):475-85. doi: 10.3748/wjg.v20.i2.475.

  PMID: 24574716 BACKGROUND

• Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med (Lond). 2001 Jan-Feb;1(1):54-60. doi: 10.7861/clinmedicine.1-1-54.

  PMID: 11358078 BACKGROUND

• Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012 Dec;56(6):2125-33. doi: 10.1002/hep.25936. Epub 2012 Aug 31.

  PMID: 22767302 BACKGROUND

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle investigator

Study Record Dates

• First Submitted: October 23, 2021
• First Posted: November 3, 2021
• Study Start: July 1, 2020
• Primary Completion: October 30, 2020
• Study Completion: April 30, 2021
• Last Updated: November 3, 2021

Record last verified: 2020-04

Locations

EG (1)